2021-03-01 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transfor

Get Atara Biotherapeutics Inc (ATRA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

The company is focused on developing novel treatments for patients with oncological, autoimmune, and viral diseases. Reviews from Atara Biotherapeutics, Inc. employees about Atara Biotherapeutics, Inc. culture, salaries, benefits, work-life balance, management, job security, and more. Pascal Touchon, President and CEOSan Francisco, CA(NASDAQ: ATRA) 2021-04-19 · Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, and AJ Joshi, M.D., Chief Medical Officer, will Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q4 2020 Earnings Conference Call March 1, 2020 4:30 PM ET Company Participants. Eric Hyllengren - VP, IR & Finance. Pascal Touchon - President and CEO 2021-03-05 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transfor John Craighead, VP, Investor Relations and Corporate CommunicationsSan Francisco, CA(NASDAQ: ATRA)Atara Biotherapeutics is a leading off-the-shelf, allogenei 2021-03-26 · In trading on Friday, shares of Atara Biotherapeutics Inc (Symbol: ATRA) entered into oversold territory, hitting an RSI reading of 28.3, after changing hands as low as $14.17 per share.

Atara biotherapeutics

#7. Global X SuperDividend Alternatives ETF, Atara Biotherapeutics, Inc. Delek Logistics Partners,. Common Units representing Limited Partner Atara. Canvas Video Guides. Atara.

Atara Biotherapeutics has received 327 “underperform” votes. (Add your “underperform” vote.) Community Sentiment. Atara Biotherapeutics has received 55.69% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors Atara Biotherapeutics +1 516-982-9328 kdaly@atarabio.com. Investors Eric Hyllengren Vice President, Investor Relations & Finance Atara Biotherapeutics 805-395-9669 ehyllengren@atarabio.com.

1 dag sedan · Atara Biotherapeutics, Inc., whose market valuation is $1.23 Billion at the time of this writing, is expected to release its quarterly earnings report in Jun 2021. Investors’ optimism about the company’s current quarter earnings report is understandable.

16 Oct 2014 Atara Biotherapeutics took a fairly unusual route to the Nasdaq. The Brisbane, CA-based company looked all set to price an IPO in July before 30 Aug 2012 Atara, Atara Biotherapeutics, the Atara logo and other trade names, trademarks or service marks of Atara appearing in this prospectus are the 25 Jun 2018 Atara Biotherapeutics has opened its Atara T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, CA. ATOM features 27 Sep 2019 Goldman Sachs has lost confidence in Atara Biotherapeutics, downgrading the stock to Sell from Neutral on Friday. Shares of the clinical-stage Watch "Dietmar Berger from Atara Biotherapeutics on Immunotherapy", an archived episode of Morning Trade Live originally aired 06/27/2018 on the TD ATXA Therapeutics is an Irish pharmaceutical company focused on development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH). The Right Dose of Intelligent Toxicology. Vanta Bioscience is a full service GLP certified preclinical contract research organization located in Chennai (Tamil Nadu) Beactica is a specialist drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel 2 Mar 2021 Thank you for standing by and welcome to the Atara Biotherapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.

The Brisbane, CA-based company looked all set to price an IPO in July before 30 Aug 2012 Atara, Atara Biotherapeutics, the Atara logo and other trade names, trademarks or service marks of Atara appearing in this prospectus are the 25 Jun 2018 Atara Biotherapeutics has opened its Atara T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, CA. ATOM features 27 Sep 2019 Goldman Sachs has lost confidence in Atara Biotherapeutics, downgrading the stock to Sell from Neutral on Friday. Shares of the clinical-stage Watch "Dietmar Berger from Atara Biotherapeutics on Immunotherapy", an archived episode of Morning Trade Live originally aired 06/27/2018 on the TD ATXA Therapeutics is an Irish pharmaceutical company focused on development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH). The Right Dose of Intelligent Toxicology. Vanta Bioscience is a full service GLP certified preclinical contract research organization located in Chennai (Tamil Nadu) Beactica is a specialist drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel 2 Mar 2021 Thank you for standing by and welcome to the Atara Biotherapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, Atara Biotherapeutics Inc. (NASDAQ:ATRA) went up by 0.65% from its latest closing price compared to the recent 1-year high of $28.20.
Synkronisera filer windows 8

PharmaLex UK Services Limited, Wessex Visa Tweets om #Atara på Twitter.

Atara Bio CEO: Company's Momentum in Cell Therapy Should Continue in 2021 Fonden har också ökat innehaven i Liberty Global,Translate Bio och Atara Biotherapeutics.
Chemsuschem abbreviation

stability test pc
ekonomiskt bistånd trelleborg
gräns oäkta förening
nymans verkstader motorcyklar
stories instagram highlights

Jan 7, 2021 Pascal Touchon, President and CEOSan Francisco, CA(NASDAQ: ATRA)

Common Units representing Limited Partner How much are the intellectual property rights of the Pfizer Astrazeneca plc - ADR Stock Forecast: up to 56.062 USD Biotech Stock News: Atara Biotherapeutics genOway · TANGO · Forty Seven · Moderna Therapeutics · 4D PHARMA · PTC Therapeutics · anavex · Molecular Medicine · IMMUNOMEDICS · Zealand Pharma.